Date:9/16/2009

BA (Monday, Sept. 21, 2009, 12:45 -13:00 CEST) -- Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: Results of a randomized Phase 3 study Lead Author: Stopeck, A. Abstract No. 2LBA (Tuesday, Sept. 22, 2009, 14:15 - 14:30 CEST) -- Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer Lead Author: Smith, M. Abstract No. 7005 (Monday, Sept. 21, 2009, 12:15 -12:45 CEST) Vectibix -- Randomized Phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC) Lead Author: Peeters, M. Abstract No. 14LBA (Tuesday, Sept. 22, 2009, 10:45 - 11:00 CEST) -- Randomized Phase 3 study of panitumumab with FOLFOX compared to FOLFOX alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): The PRIME trial Lead Author: Douillard, J.Y. Abstract No. 10LBA (Thursday, Sept. 24, 2009, 11:00 - 11:15 CEST)

An analyst/investor event will also be held from the Congress on September 24th, at 6:30 a.m. ET to discuss data presented at ECCO-ESMO. A webcast of the event can be found on Amgen's Web site at www.amgen.com, under Investors. The audio webcast will be archived and available for replay for at least 72 hours.

About Denosumab

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad a
'/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
4. Amgen to Present at the Barclays Capital Global Healthcare Conference
5. Amgen Announces Webcast of 2009 First Quarter Financial Results
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen Highlights Data to Be Presented at ASCO
10. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
11. Loyola fellow receives Amgen grant to study treatments for older leukemia patients